
Eli Lilly drug slows Alzheimer’s progression by 35% in trial
An experimental Alzheimer’s drug developed by Eli Lilly and Co LLY.N slowed cognitive decline by 35% in a closely watched late-stage trial, the company said on Wednesday, raising hopes ...